Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 8/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | TYK2 | P29597 | 2/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.41 |
| ▸ | TNNI3K | Q59H18 | 4/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31247372 | 0.84 | CDK1 (0.46) | GCKJAK1TYK2GRM4TNNI3K | |
| SCHEMBL31300245 | 0.84 | CDK1 (0.46) | GCKJAK1TYK2GRM4TNNI3K | |
| SCHEMBL31247520 | 0.80 | GRM5 (0.54) | GCKJAK1TYK2TNNI3KHPGD | |
| SCHEMBL25242188 | 0.79 | TYK2 (0.45) | JAK1TYK2TNNI3K | |
| SCHEMBL31247496 | 0.79 | GRM5 (0.52) | GCKTYK2TNNI3KLMNAAR | |
| SCHEMBL31247704 | 0.76 | JAK1 (0.40) | GCKJAK1TYK2GRM4LMNA | |
| SCHEMBL31247474 | 0.76 | TYK2 (0.43) | GCKJAK1TYK2TNNI3KJAK2 | |
| SCHEMBL31247362 | 0.75 | TYK2 (0.41) | GCKJAK1TYK2TNNI3KJAK2 | |
| SCHEMBL31247547 | 0.75 | BRAF (0.40) | GCKJAK1TYK2TNNI3KJAK2 | |
| SCHEMBL31247522 | 0.75 | JAK1 (0.41) | GCKJAK1TYK2TNNI3KJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719394-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ATOMWISE INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20240425484-A1 | INHIBITORS OF TYK2 | Atomwise Inc. | 2024-12-26 | — | — | US | disclosed |
| WO-2024250010-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | TYK2, FRK, DYRK2 | GCK 438/4885JAK1 9/4885TYK2 1/4885 |
| US-20240425484-A1 | INHIBITORS OF TYK2 | TYK2, LCK, JAK2 | GCK 837/4885JAK1 5/4885TYK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.